Abstract: Objective To study on the value of FibroScan in evaluating the efficacy of antiviral therapy for patients with chronic hepatitis B (CHB) and slightly elevated serum level of alanine aminotransferase (ALT).Methods Eighty cases of chronic hepatitis B patients with mildly elevated ALT were divided into an observation group and a control group according to different treatments that they had received. Patients in the observation group were treated with nucleoside antiviral drug (N=52), while patients in the control group were treated with glycyrrhizin in combination with five ester capsule and bicyclol) (N=28). Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), hepatitis B viral load (HBV DNA) and Fibroscan values were compared between these two groups of patients at before and 12 months after the treatments. Results After 12 months of treatments, ALT and AST levels in both groups of patients were significantly lower than those before treatments (P<0.05), and the above indexes in the observation group were significantly lower than those in the control group (P<0.05). The HBV DNA load and FibroScan values in the observation group were significantly lower than those before treatment (P<0.05), and both indexes were significantly lower than those in the control group (P<0.05).Conclusion FibroScan has a good evaluating performance for antiviral treatment in patients with chronic hepatitis B and mildly elevated ALT, which is worthy of active promotion in clinical practice.

Key words: FibroScan, Alanine aminotransferase, Chronic hepatitis B, Antiviral therapy